Electrical device for patients with glioblastoma met with support, skepticism: Some question the device's efficacy, others tout it as a new standard of care

C. Printz

DOI: https://doi.org/10.1002/cncr.28991

IF: 6.9209

2015-04-01

Cancer

Abstract:969 R leading a study of an electrical device that treats glioblastomas tout it as a new standard of care for the disease, whereas other physicians question its effectiveness. Roger Stupp, MD, principal investigator of the study and director of the Cancer Center at the University Hospital Zurich in Switzerland, presented the results of the study at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology held in Miami, Florida, in November, 2014. The device, formerly known as NovoTTF and now called Optune, is a noninvasive therapy that targets dividing cancer cells in the brain. It creates alternating, “wave-like” electric fields called tumor-treating fields (TTFields) that travel across the upper part of the brain in different directions to help slow or stop recurrent glioblastoma multiforme (GBM) cancer cells from dividing. It is manufactured by Novocure Inc, a commercial stage oncology company headquartered in Jersey, an English island off the coast of France, and is available at 150 cancer centers across the United States. The portable, wearable device, which costs $21,000 per month, delivers an antimitotic, anticancer therapy through 4 transducer arrays placed on the surface of a patient’s scalp that are changed every 4 to 7 days. The device must be worn at least 18 hours each day, and patients must shave their scalps to wear it. Also included with the system is a portable battery and a lightweight field generator that produces the electric fields. Researchers say the most common side effect is skin irritation. Because patients with glioblastomas have very limited treatment options and a median survival of 15 months, scientists involved in the study view the device as an opportunity for these patients. Although it is not a cure or a replacement for surgery, chemotherapy, or radiotherapy, interim analysis results from Novocure’s EF-14 phase 3 clinical trial demonstrated that the device extended both overall survival (OS) and progressionfree survival by 3 months in patients with newly diagnosed glioblastoma when used in combination with the chemotherapy drug temozolomide. Other physicians have yet to be convinced of the device’s efficacy. Several say they are taking a “wait-and-see” attitude until they view the published results of the study presented at the November meeting. In addition, the Centers for Medicare and Medicaid Services does not provide coverage for the device, and it is currently under review with the National Comprehensive Cancer Network’s central nervous system tumor guidelines committee. “The data was very sketchy, at least to my eye, and the study design raised a lot of questions about whether this really is efficacious or not,” says W.K. Alfred Yung, MD, chair of the department of neuro-oncology at The University of Texas MD Anderson Cancer Center in Houston. “As a group, we decided not to prescribe the treatment.” Tracy Batchelor, MD, MPH, director of the division of neuro-oncology at Massachusetts General Hospital in Boston, says, “It’s still early in terms of the data being presented. This is a highly lethal type of cancer, and we’re in desperate need of new therapies; of course we’d be open to any type of therapy that clearly extends survival and is safe.”